TY - JOUR
T1 - Inflammation in AKI
T2 - Current understanding, key questions, and knowledge gaps
AU - Rabb, Hamid
AU - Griffin, Matthew D.
AU - McKay, DIanne B.
AU - Swaminathan, Sundararaman
AU - Pickkers, Peter
AU - Rosner, Mitchell H.
AU - Kellum, John A.
AU - Ronco, Claudio
N1 - Publisher Copyright:
Copyright © 2016 by the American Society of Nephrology.
PY - 2016/2
Y1 - 2016/2
N2 - Inflammation is a complex biologic response that is essential for eliminating microbial pathogens and repairing tissue after injury. AKI associates with intrarenal and systemic inflammation; thus, improved understanDing of the cellular and molecular mechanisms underlying the inflammatory response has high potential for identifying effective therapies to prevent or ameliorate AKI. In the past decade, much knowledge has been generated about the fundamental mechanisms of inflammation. Experimental work in small animal models has revealed many details of the inflammatory response that occurs within the kidney after typical causes of AKI, incluDing insights into the molecular signals released by dying cells, the role of pattern recognition receptors, the diverse subtypes of resident and recruited immune cells, and the phased transition from destructive to reparative inflammation. Although this expansion of the basic knowledge base has increased the number of mechanistically relevant targets of intervention, progress in developing therapies that improve AKI outcomes by modulation of inflammation remains slow. In this article, we summarize the most important recent developments in understanDing the inflammatorymechanisms ofAKI, highlight key limitations of the commonly used animal models and clinical trial designs that may prevent successful clinical application, and suggest priority approaches for research toward clinical translation in this area.
AB - Inflammation is a complex biologic response that is essential for eliminating microbial pathogens and repairing tissue after injury. AKI associates with intrarenal and systemic inflammation; thus, improved understanDing of the cellular and molecular mechanisms underlying the inflammatory response has high potential for identifying effective therapies to prevent or ameliorate AKI. In the past decade, much knowledge has been generated about the fundamental mechanisms of inflammation. Experimental work in small animal models has revealed many details of the inflammatory response that occurs within the kidney after typical causes of AKI, incluDing insights into the molecular signals released by dying cells, the role of pattern recognition receptors, the diverse subtypes of resident and recruited immune cells, and the phased transition from destructive to reparative inflammation. Although this expansion of the basic knowledge base has increased the number of mechanistically relevant targets of intervention, progress in developing therapies that improve AKI outcomes by modulation of inflammation remains slow. In this article, we summarize the most important recent developments in understanDing the inflammatorymechanisms ofAKI, highlight key limitations of the commonly used animal models and clinical trial designs that may prevent successful clinical application, and suggest priority approaches for research toward clinical translation in this area.
UR - http://www.scopus.com/inward/record.url?scp=84970924677&partnerID=8YFLogxK
U2 - 10.1681/ASN.2015030261
DO - 10.1681/ASN.2015030261
M3 - Article
SN - 1046-6673
VL - 27
SP - 371
EP - 379
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 2
ER -